# Raja Atreya

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/raja-atreya/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,688 |
| Field | Inflammatory Bowel Disease |
| h-index | 68 |
| i10-index | 202 |
| Last Known Institution | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| OpenAlex ID | https://openalex.org/A5034003178 |
| ORCID iD | https://orcid.org/0000-0002-8556-8433 |
| Works | 651 |

## Researcher papers

- [Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo](https://scholariq.org/papers/blockade-of-interleukin-6-trans-signaling-suppresses-t-cell-resistance-against/)
- [CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes](https://scholariq.org/papers/cd28-dependent-rac1-activation-is-the-molecular-target-of-azathioprine-in/)
- [Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn’s Disease](https://scholariq.org/papers/mongersen-an-oral-i-smad7-i-antisense-oligonucleotide-and-crohn-s-disease/)
- [In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease](https://scholariq.org/papers/in-vivo-imaging-using-fluorescent-antibodies-to-tumor-necrosis-factor-predicts/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-medical-treatment-2/)
- [Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study](https://scholariq.org/papers/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active/)
- [ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-surgical-treatment-2/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Helicobacter pylori-related gastroenterology studies](https://scholariq.org/topics/helicobacter-pylori-related-gastroenterology-studies/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)

## Researcher university

- [Friedrich-Alexander-Universität Erlangen-Nürnberg](https://scholariq.org/institutions/friedrich-alexander-universitat-erlangen-nurnberg/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.